

Policies Repository



Policy Title Fenofibric Acid (Trilipix)

Policy Number FS.CLIN.72

Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on product line, group or contract. Some medications may be subject to precertification, age, gender or quantity edits. Individual member benefits must be verified.

This Pharmacy Policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety or FDA approval may have changed. If the Medical/Pharmacy Reviewer is aware of any new information on the subject of this document, please provide it promptly to the Medical/Pharmacy Policy Department. This information may include new FDA approved indications, withdrawals or other FDA alerts. This type of information is relevant not only when considering whether this Policy should be updated, but also when applying it to current requests for coverage.

Members are advised to use participating pharmacies in order to receive the highest level of benefits.

Policy **Fenofibric Acid (Trilipix)** is indicated in combination with a statin to reduce TG and increase HDL-C in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL-C goal. Fenofibric Acid (Trilipix) is also indicated as monotherapy to reduce TG in patients with severe hypertriglyceridemia and as monotherapy to reduce elevated LDL-C, Total-C, TG and apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia.

The use of Fenofibric Acid (Trilipix) requires prior authorization (ie, clinical pharmacy and/or Medical Director review).

Policy Description Fenofibric Acid (Trilipix) is a peroxisome proliferator receptor alpha activator. Trilipix increases lipolysis and elimination of triglyceride rich particles from plasma by activating lipoprotein lipase and reducing the production of Apo CIII (an inhibitor of lipoprotein lipase activity). The resulting decrease in TG produces an alteration in the size and composition of LDL from small dense particles to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. Activation of peroxisome proliferators receptor alpha also induces an increase in the synthesis of HDL-C and Apo AI and AII.

Policy Guideline Inclusion Fenofibric Acid (Trilipix) is approved when **all** of the following inclusion criteria are met:

- Documentation of a diagnosis of mixed dyslipidemia, hypertriglyceridemia, or hyperlipidemia
- Documentation of a trial and failure of a fibric acid derivative

Policy Guideline Exclusion Fenofibric Acid (Trilipix) is denied when **any** of the following exclusion criteria are present:

- No documentation of a diagnosis of mixed dyslipidemia, hypertriglyceridemia, or hyperlipidemia
- No documentation of a trial and failure of a fibric acid derivative

Policy List of Applicable Drugs

Brand Name	Generic Name
Trilipix	Fenofibric Acid

Dosing and Administration

Refer to the specific manufacturer's prescribing information for administration and dosage details for each specific agent.

Policy References

Abbott's Phase III Fenofibrate works with Statins. Available at www.thepinksheet.com. Accessed January 13, 2009.

Facts and Comparisons [Trilipix]. Available at www.factsandcomparisons.com. Accessed January 13, 2009.

Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. *Circulation* 2004; 110:227-239.

Micromedex website [Trilipix]. Available at www.micromedex.com. Accessed January 13, 2009.

Trilipix [package insert]. Chicago, IL: Abbott Pharmaceuticals; 2008.

Policy Link to Related Policies**Printed**

07/06/2009 09:21:58

The Policy Bulletins on this web site were developed to assist Independence Blue Cross and its subsidiaries ("IBC") in administering the provisions of the respective benefit programs, and do not constitute a contract. If you are an IBC member, please refer to your specific benefit program for the terms, conditions, limitations and exclusions of your coverage. IBC does not provide health care services, medical advice or treatment, or guarantee the outcome or results of any medical services/treatments. The facility and professional providers are responsible for providing medical advice and treatment. Facility and professional providers are independent contractors and are not employees or agents of IBC. If you have a specific medical condition, please consult with your doctor. IBC reserves the right at any time to change or update its Policy Bulletins. © 2008 Independence Blue Cross. All Rights Reserved. Current Procedural Terminology © 2008 American Medical Association. All Rights Reserved.